91 results about "NY-ESO-1" patented technology

The invention relates to members of the SSX family of genes, as well as their uses. Also a part of the invention are peptides derived from SSX molecules and the NY-ESO-1 molecule, which form complexes with HLA molecules, leading to lysis of cells presenting these complexes, by cytolytic T cells.

The invention relates to variant peptides which bind to HLA molecules, leading to lysis of cells via cytolytic T cell lines. The variants are based upon NY-ESO-1 peptides. The peptides can be incorporated into immune tetramers, which are useful as T cell sorters.

The invention relates to variant peptides which bind to HLA molecules, leading to lysis of cells via cytolytic T cell lines. The variants are based upon NY-ESO-1 peptides. The peptides can be incorporated into immune tetramers, which are useful as T cell sorters.

The invention relates to methods for determining tumor status by determining antibodies specific to NY-ESO-1 in patient samples. One can determine whether a cancerous condition is progressing, regressing, or remaining stable by determining antibodies against NY-ESO-1 in a patient sample, and comparing the value obtained to a prior value. When the tumor in question expresses NY-ESO-1, a change in this value is indicative of a change in status of the cancerous condition.

The invention relates to antibodies which bind to the cancer associated antigen NY-ESO-1. Both polyclonal and monoclonal antibodies are part of the invention, as are chimeric forms of the antibodies, and binding portions of antibodies. Uses of these antibodies are described. Also described are truncated, recombinant forms of the cancer associated antigen.

The invention discloses a detection kit used for detecting the serum autoantibody of mammals. The detection kit comprises an antigen protein, wherein the antigen protein is a combination of five or more out of p53, Annexin1, CAGE, NY-ESO-1, HuD, Cyclin D, PGP9.5, GBU4-5, MDM2, GAGE7, XAGE1b, SOX2, MAGE A1 and MAGE A4. The detection kit adopts a group of novel antigen combination corresponding to the autoantibody of a biomarker related to cancers, utilizes biotins to form characteristics of a polymer to envelope the antigen protein, and uses an anti-human label peptide as a standard of quantitative detection, thus increasing the detection sensibility and accuracy of the serum autoantibody, and providing an optimized detection method for using the autoantibody to carry out cancer diagnosis.

The invention relates to variant peptides which bind to HLA molecules, leading to lysis of cells via cytolytic T cell lines. The variants are based upon NY-ESO-1 peptides. The peptides can be incorporated into immune tetramers, which are useful as T cell sorters.

The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts.

Immunostimulatory NY-ESO-1 epitopes recognized by MHC-DRB3*0202 (DR52b) or DRB1*0101 (DR1) restricted T cells are described. Methods for their use in diagnostic and therapeutic approaches are also provided. Further, methods for the generation and isolation of MHC class II molecules, either “empty” or peptide-loaded, are provided. Methods for the assembly of MHC class II multimers, for example, tetramers, are also provided. Methods for the detection of T cells binding to specific peptide-loaded MHC class II molecules are also described herein.

The invention relates to an esophageal squamous cell carcinoma autoantibody molecular marker model and an application thereof. The molecular model mainly comprises an ALDOA autoantibody, an ENO1 autoantibody, a p53 autoantibody, and an NY-ESO-1 autoantibody, and can be used for preparing a kit for distinguishing esophageal squamous carcinoma patients and healthy medical examiners. The kit for detecting esophageal squamous cell carcinoma patients mainly comprises recombinant ALDOAD protein, recombinant ENO1 protein, recombinant p53 protein, and recombinant NY-ESO-1 protein. According to the esophageal squamous cell carcinoma autoantibody molecular marker model and the application thereof, the ENO1 autoantibody is found to be elevated in serum level in the esophageal squamous carcinoma patients for the first time, and is jointly detected with the ALDOA autoantibody, the p53 autoantibody, and the NY-ESO-1 autoantibody for distinguishing the esophageal squamous cell carcinoma patients andthe healthy medical examiners, and has a better distinguishing effect than a single index detection; and in addition, the detection method adopted by the invention is an enzyme-linked immunosorbent assay indirect method, is simple and convenient to implement, has good sensitivity and specificity, and is a method which is mature and reliable and can be widely used in base layer hospitals.

The present invention provides novel vaccine formulations for the treatment of cancer antigens. The vaccine comprises a modified MAGE-3 antigen, a NY-ESO-1 antigen, and an adjuvant comprising a saponin and a immunostimulatory oligonucleotide.

The invention discloses a liquid chip kit for detecting a lung cancer autoantibody. The kit includes: microspheres coupling antigen proteins, a biotin labeled second antibody, streptavidin-phycoerythrin, a reaction buffer and a dilution buffer solution. The antigen proteins are at least two of p62, NY-ESO-1, p53 and CAGE, wherein the microspheres coupling different antigen proteins have different color codes. The second antibody is anti-human immunoglobulin G. The liquid chip kit for detecting the lung cancer autoantibody provided in the invention realizes joint detection of four antibodies in serum on a liquid chip technology platform, and takes the p62 antibody, the NY-ESO-1 antibody, the p53 antibody and the CAGE antibody as marks, has high detection accuracy, and provides a new idea for early diagnosis of lung cancer.

The invention relates to a preparation process of dendritic cell targeted nanoliposome tumor vaccine and the tumor vaccine can be absorbed and processed targetedly by antigen presenting cells in human body and can be used to induct the antigen presenting cells to mature. The preparation process of the invention comprises the following steps: (1) extracting alpha1 and 3Ga1 glycolipid from rabbit red cell membranes: breaking down the concentrated red cells of the rabbit, mixing cell membranes with chloroform and methanol to react, filtrating to remove granule constitutes, adding double distilled water to obtain oil phase and water phase; collecting water phase and removing methanol and trace chloroform to obtain alpha1-3Ga1-triglyceride composite for standby; and (2) adding a certain amount of alpha1 and 3Ga1 glycolipid in trichloromethane to dissolve, adding the obtained product in a certain amount of yolk lecithin, cholesterol and PEG2000-DSPE mixture, vibrating the obtained mixture for dissolving, performing rotating film evaporation to obtain liposome film, adding PBS buffer solution with 1mg/ml of NY-ESO-1 protein and performing ultrasonic emulsification to obtain the product provided by the invention.

The invention provides a T cell receptor (TCR) which can be specifically combined with an NY-ESO-1 antigen short peptide SLLMWITQC. The antigen short peptide SLLMWITQC and HLA A0201 can form a composite which is presented onto the surface of the cells together. The invention also provides a nucleic acid molecule encoding the TCR and a carrier containing the nucleic acid molecule, and also provides a cell that transduces the TCR.

The invention relates to peptides which consist of amino acid sequences found in the NY-ESO-1 molecule, which bind to MHC-Class II molecules. These can be used alone, or in combination with other peptides.

The invention relates to the discovery that administration of NY-ESO-1 protein, in combination with a saponin based adjuvant leads to an unexpectedly strong immune response against NY-ESO-1 expressing cells. Preferably, the combination is administered intramuscularly.

The invention provides a TCR (T cell receptor) capable of being specifically bound with a short peptide LLMWITQCF deriving from an NY-ESO-1 antigen. The short peptide LLMWITQCF and HLA A2402 can form a compound to be transferred to the surface of a cell together. The invention further provides a nucleic acid molecule capable of encoding the TCR and a supporter containing the nucleic acid molecule. Besides, the invention further provides a cell for transducing the TCR.